# Canadian Myeloma Research Group: Phase 1 study in Relapsed Refractory Multiple Myeloma (RRMM) (108 participants)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | Canadian Myeloma Research Group |
| Sponsor type | Academic and hospital |
| Study | Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) |
| NCT ID | NCT07831122 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Relapsed Refractory Multiple Myeloma (RRMM) |
| Intervention types | drug, biological |
| Target enrollment | 108 |
| Site countries | Canada |
| Posted | 2026-09-21 |
| Planned start | 2026-12 |
| Event | Newly registered study |
| Event date | 2026-09-21 |

## Why this score
- 108 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07831122). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.